Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00452218 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Sorafenib

Sponsor

University of Chicago

Collaborators

[object Object]